Earendil Labs Deal History & Licensing Activity
Earendil Labs is a biotech. Over the past three years, Earendil Labs has been involved in 3 licensing and acquisition transactions, with a primary focus on Bispecific Antibodies (4 deals).
Deals (12mo)
3
Active Trials
0
Top Modality
Bispecific Antibodies
Focus Area
Other
Earendil Labs Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Earendil Labs in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Undisclosed bispecific antibody oncology asset | Genentech/Roche | Bispecific Antibodies | Discovery | collaboration | Sep 24, 2026 |
| WuXiTecan-2 | WuXi XDC | ADC | Preclinical | license | Feb 27, 2026 |
| Undisclosed | Sanofi | Bispecific Antibodies | Discovery | collaboration | Jan 5, 2026 |
Earendil Labs Pipeline Focus
Therapeutic areas and modalities where Earendil Labs is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Earendil Labs Strategic Signals
Key indicators of Earendil Labs's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches Earendil Labs's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Other assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
ADC Benchmarks
Upfront, milestone, and royalty benchmarks for adc deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Earendil Labs Licensing & Deal Activity
Earendil Labs is a biotech company that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Earendil Labs ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Earendil Labs include Other (2 deals and trials), Oncology (2 deals and trials), and Immunology (2 deals and trials). In terms of modality, Earendil Labs has shown particular interest in bispecific antibodies, adc.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Earendil Labs and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Earendil Labs's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.